Sisthaema Hevo T 2ml

Sisthaema Hevo +T 2ml

SISTHAEMA HEVO T is a hydrogel for intradermal injections with a breakthrough and patented formulation containing a combination of hyaluronic acid and trehalose, with proven longer persistence in tissues, compared to other formulations containing linear hyaluronic acid.

It provides a bioregenerative effect ("Sisthaemic Dermal Regeneration"), adds volume to the skin and deeply hydrates it.

Areas of application

Cheekbones,
Nasolabial folds,
Marionette lines,
Loss of definition in the facial oval,
The back of the face.
Composition / Action

Unique formulation = best hydration effects

1 2ml syringe contains 50 mg of hyaluronic acid and 20 mg of trehalose

Hyaluronic acid in two molecular weights 1200-1500 kDa and 200-400 kDa, and trehalose - a disaccharide that is responsible for protecting hyaluronic acid structures from accelerated destruction and final breakdown. In addition, trehalose protects fibroblasts from dangerous dehydration, which can interfere with their normal function.

Natural lifting effect
When the Sisthaemic Dermal Regeneration process occurs, the skin begins to regenerate itself, producing new type III collagen fibers, resulting in a natural lifting of tissues in a way that harmoniously enhances your facial features. The result? A younger version of you.

Volume and deep hydration
High- and low-molecular-weight ingredients add volume to tissues and deeply hydrate them. SISTHAEMA HEVO T's unique combination of ingredients has the ability to attract much more water compared to other linear hyaluronic acid products, allowing for deep skin hydration.

Sisthaemic Dermal Regeneration Process
SISTHAEMA HEVO T is the only product capable of stimulating actual skin bioregeneration, rejuvenating the skin naturally and producing long-lasting and ever-improving results.

The purest hyaluronic acid and fewer side effects
SISTHAEMA HEVO T contains hyaluronic acid (HA) in its purest form, with the lowest concentration of endotoxins, making the risk of side effects caused by use almost non-existent.

Young collagen
Typically, hyaluronic acid products primarily stimulate the production of fibrotic (type I) collagen.

SISTHAEMA HEVO T has the ability to stimulate the production of primarily reticular collagen (type III), also often referred to as "young collagen," because it is found in the greatest amount in younger skin.

Hyaluronic acid and trehalose
In addition to hyaluronic acid, the formulation also contains TREHALOSE, a disaccharide that has the ability to protect hyaluronic acid from natural breakdown processes, allowing hyaluronic acid to persist in the skin and last longer than other non-cross-linked hyaluronic acid-based injectables. Trehalose also has an impressive water-binding capacity, keeping the skin tight and hydrated for longer.

Two different molecular weights

SISTHAEMA HEVO T contains ingredients with two molecular weights. Most of them are high-molecular-weight ingredients - they volumize the tissue, stimulate the production of type III collagen and attract water for a hydrating effect. Low-molecular-weight ingredients make the gel softer, so more natural results can be achieved, and the administration procedure itself is much easier.

HA fragmentation

During the manufacturing process, hyaluronic acid undergoes fragmentation - and the resulting fragments precisely interact with specific receptors in the skin (CD 44), stimulating the production of the correct type of collagen, namely collagen type III (young collagen).

Sisthaem administration technique

Sisthaema should be administered intradermally using an in-line or spot injection technique at a medium-depth level.

The product can be administered using a 5 point technique.

SISTHAEMA HEVO T comes with two 30G needles, some of the thinnest on the market.

How often should treatments be performed?

In order to gradually achieve better results and activate the effect of "Sisthaemic Dermal Regeneration", depending on the condition of the skin and the degree of photo-aging and chronological aging, it is necessary to implement a full protocol of three sessions, with an interval of 15 days between them, followed by reminder sessions every 30 days for 3 months.